Concord Biotech Ltd.

₹1,046.4

-14 (-1.3%)

CONCORDBIO Share Price

Pharmaceuticals & Biotechnology

As on April 13, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 11,008 Cr

P/E Ratio29.46

Dividend Yield1.02 %

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	1,048.78	Bearish
10-DMA	1,035.19	Bullish
20-DMA	1,072.07	Bearish
50-DMA	1,140.11	Bearish
100-DMA	1,250.04	Bearish
200-DMA	1,456.22	Bearish

Historical Performance

1 Year

-36.7%

3 Years

N/A

5 Years

N/A

10 Years

N/A

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Net Sales	12,001	10,169	8,532	7,129	6,169
Total Expenditure	6,932	5,848	5,046	4,390	2,890
Other Income	444	338	353	234	138
Operating Profit	5,513	4,660	3,839	2,973	3,417
Interest	10	32	98	61	10
Depreciation	544	536	540	500	275
Profit Before Tax	4,946	4,126	3,220	2,375	3,127
Consolidated Net Profit	3,716	3,081	2,401	1,749	2,348
Adjusted EPS	36	29	23	17	22

Compounded Sales Growth

10 Years:18.6

5 Years:18.6

3 Years:11

TTM:3.4

Compounded Profit Growth

10 Years:17.1

5 Years:17.1

3 Years:16.3

TTM:3.8

Stock Price CAGR

10 Years:N/A

5 Years:N/A

3 Years:N/A

TTM:-39.6

Return on Equity

10 Years:N/A

5 Years:22.4

3 Years:22.9

last year:35.5

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Share Capital	105	105	105	95	95
Total Reserves	18,023	15,162	12,795	10,937	9,899
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	375	319	321	544	774
Other Current Liabilities	550	383	616	660	536
Short Term Borrowings	4	---	---	43	51
Total Liabilities	20,343	17,007	15,140	15,019	13,127
Capital Work in Progress	501	2,115	1,727	742	179
Long Term Loans & Advances	120	128	116	2,210	1,406
Currents Investments	3,165	2,437	1,369	735	1,410
Short Term Loans and Advances	274	211	157	104	338
Total Current Assets	11,352	8,962	7,277	6,327	6,071
Total Assets	20,343	17,007	15,140	15,019	13,127
Adjusted Book Value	173	146	123	105	96

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a high PE of 29.46, indicating expensive valuation or elevated growth expectations.
Over the last three years, the stock delivered a moderate 3-year price CAGR of 5.4%, reflecting average market performance.
The stock carries a low beta of 0.5, suggesting lower volatility than the broader market.
In the last financial year, the company reported an EBITDA of ₹5513 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹12001 million, indicating a large and established business.

Investment Calculator

Investment Amount:

₹

Investment Amount: ₹ 1000000

Current Value: ₹ 603773.6

No. of Shares: 577 (Approx)

Performance:-39.6%

P/L: ₹-396226.4

NIFTY Performance: 2.2%

1 day Top Gainers